Portage Biotech Stock Gross Profit
| PRTG Stock | USD 4.41 0.15 3.29% |
Portage Biotech fundamentals help investors to digest information that contributes to Portage Biotech's financial success or failures. It also enables traders to predict the movement of Portage Stock. The fundamental analysis module provides a way to measure Portage Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Portage Biotech stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | -62.1 K | -59 K | |
| Gross Profit Margin | (40.09) | (42.09) |
Portage | Gross Profit |
Portage Biotech Company Gross Profit Analysis
Portage Biotech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Portage Biotech Gross Profit | (59.0K) |
Most of Portage Biotech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Portage Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Portage Gross Profit Driver Correlations
Understanding the fundamental principles of building solid financial models for Portage Biotech is extremely important. It helps to project a fair market value of Portage Stock properly, considering its historical fundamentals such as Gross Profit. Since Portage Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Portage Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Portage Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
Portage Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Portage Biotech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Portage Biotech could also be used in its relative valuation, which is a method of valuing Portage Biotech by comparing valuation metrics of similar companies.Portage Biotech is currently under evaluation in gross profit category among its peers.
Portage Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Portage Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Portage Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Portage Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 5.52 M | ||||
| Shares Outstanding | 1.65 M | ||||
| Shares Owned By Insiders | 29.80 % | ||||
| Shares Owned By Institutions | 17.80 % | ||||
| Number Of Shares Shorted | 19.77 K | ||||
| Price To Book | 5.19 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Current Ratio | 11.73 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (68.17) X | ||||
| Target Price | 140.0 | ||||
| Beta | 99.48 | ||||
| Market Capitalization | 7.26 M | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
| Working Capital | 4.82 M | ||||
| Net Asset | 7.78 M |
About Portage Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Portage Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Portage Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Portage Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Check out Portage Biotech Piotroski F Score and Portage Biotech Altman Z Score analysis. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.